Successful therapy of retroperitoneal fibrosis due to IgG4-related disease with rituximab, cyclophosphamide and glucocorticoids followed by maintenance therapy wit ritutixmab

Czech version

Authors: Zdeněk Adam ¹; Aleš Čermák ²; Hana Petrášová ³; Zdeněk Řehák ⁴; Renata Koukalová ⁴; Zdeněk Fojtík ¹; Luděk Pour ¹; Ivanna Boichuk ¹; Marta Krejčí ¹; Zdeněk Král ¹; Petr Benda ⁵
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno ¹; Urologická klinika LF MU a FN Brno ²; Klinika radiologie a nukleární medicíny – LF MU a FN Brno ³; Oddělení nukleární medicíny Masarykův onkologický ústav Brno ⁴; Chirurgická klinika LF a FN Brno ⁵
Published in: Vnitř Lék 2023; 69(E-3): 4-15
Category: Case reports
doi: https://doi.org/10.36290/vnl.2023.035

Overview

Idiopathic retroperitoneal fibrosis (IRF) is a rare condition characterized by the development of a peri-aortic and peri-iliac tissue showing chronic inflammatory infiltrates and pronounced fibrosis. Ureteral entrapment with consequent obstructive uropathy is one of the most common complications, which can lead to acute renal failure and, in the long term, to varying degrees of chronic kidney disease. Common symptoms at onset include lower back, abdominal or flank pain, and constitutional symptoms such as malaise, fever, and anorexia and weight loss. Pain is frequently referred to the hip, to the groin and to the lateral regions of the leg, with nocturnal exacerbations, and typically does not modify with position.

We report a case of 56 year-old male with recurrent lower back pain and lower abdominal pain. Contrast-enhanced computed tomography and was suggestive of retroperitoneal fibrosis and unilateral ureteral occlusion. Histologic examination with immunohistochemical staining for IgG4 demonstrate IgG4-related retroperitoneal fibrosis. Therapy was started with prednison 1 mg/kg, but the tolerance of this dose was poor. Therefore the therapy was switched to combination of rituximab 375 mg/ m² on day 1, cyclophosphamide 300 mg/m² mg infusion and dexamethasone 20 mg total dose infusion on day 1 and 15 in 28 days cycle. FDG-PET/CT control in fourth month showed residual accumulation of FDG in retroperitoneal fibrotic mass, and therefore the therapy was prolonged to 8 month. The subjective symptoms of this diseases disappeared in the 8th month. Then the maintenance therapy, administration of rituximab in 6 month interval, was started.

The activity of this disease be further evaluated by FDG-PET/CT imagination.

Glucocorticoids are considered the cornerstone of therapy. The use of other immunosuppressive agents, including cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil and biological agents such as rituximab, tocilizumab and infliximab and sirolimus have been reported as a valuable option mostly in case reports, cases series and small studies. This agents allowed to reduce cumulative dose of glucocorticoids and its adverse effects. Therefore in our patients we preferred combination of rituximab cyclophosphamide s dexamethasone with lover dose of prednisonem.

This combination is preferable for patients who cannot tolerate glucocorticoids or who are likely to suffer from significant glucocorticoids -related toxicity.

Keywords:

Cyclophosphamide – rituximab – retroperitoneal fibrosis – IgG4 related disease

Sources

1. Průcha M, Beňo P, Bartůněk M, et al. Idiopatická retroperitoneální fibróza - Ormondova choroba: kazuistika. Vnitřní lékařství. 2008;54(3):282-286.

2. Němec P, Rybníčková S, Fabián P, et al. Idiopathic retroperitoneal fibrosis: an unusual cause of low back pain. Clinical rheumatology. 2008;27(3):381-384.

3. Němec P, Rybníčková S, Fabian P, et al. Idiopatická retroperitoneální fibróza: Méně častá příčina bolestí dolní části zad. Použití tamoxifenu v terapii onemocnění. Česká revmatologie. 2008;16(1):23-29.

4. Fedorko M, Krhovský M. Perirenální retroperitoneální fibróza. Urologie pro praxi. 2009;10(5):299-301.

5. Kašík J, Kolombo I, Porš J, et al. Primární retroperitoneální fibróza – morbus Ormond. Urologie pro praxi. 2008;9(3):128-132.

6. Sobotka R, Hanuš T. Primární retroperitoneální fibróza, Urologie pro praxi. 2006;7(4):156- 159.

7. Pulcer J, Staněk R, Kokoř T, et al. Fokální Ormondova choroba (idiopatická retroperitoneální fibróza). Urologie pro praxi. Březsko: Solen, 2000-. 2015;16, (Suppl. A):

8. Ormond JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol. 1948;59:1072–107.

9. Kharagjitsing H, van Eekeren R, van Puijenbroek EP, et al. Retroperitoneal fibrosis and β-blocking agents: Is there an association? Br J Clin Pharmacol. 2021;87(7):2891-2901.

10. Brasselet D, Chouchana L, Vial T, et al. Drug-induced retroperitoneal fibrosis: a case/ non-case study in the French PharmacoVigilance Database. Expert Opin Drug Saf. 2020;19(7):903-914.

11. van Bommel EF, Jansen I, Hendriksz TR, et al. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore) 2009;88:93-201.

12. Mizushima I, Kawano M. Renal Involvement in Retroperitoneal Fibrosis:Prevalence, Impact and Management Challenges. Int J Nephrol Renovasc Dis. 2021;14:279-289.

13. Švihra J, Študent V. Retroperitoneálna fibróza. Urologie pro praxi. 2016;17(1):14-16.

14. Průcha M, Kolombo I, Štádler P, Ormond's disease – IgG4-related disease. Prague Medical Report. 2015;116(3):181-192.

15. Posová H Ormondova nemoc: Imunopatologické stavy v kazuistikách. První vydání. Praha: Mladá fronta, a. s., 2016. 2016:159-163.

16. Raglianti V, Rossi GM, Vaglio A. Idiopathic retroperitoneal fibrosis: an update for nephrologists. Nephrol Dial Transplant. 2021;36(10):1773-1781.

17. Fenaroli P, Maritati F, Vaglio A. Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis. Curr Rheumatol Rep. 2021;23(3):18. doi: 10.1007/s11926-020-00966-9.

18. Kolář J, Pavrovský J, Balaš V, et al. Ileus jako první projev retroperitoneální fibrózy Rozhledy v chirurgii. 1972;51(6):341-344.

19. Kermani TA, Crowson CS, Achenbach SJ. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc. 2011;86:297-303.

20. Scheel PJ Jr, Feeley N : Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation. Medicine (Baltimore)2009;88:202-207.

21. Cronin CG, Lohan DG, Blake MA, et al. Retroperitoneal fibrosis: a review of clinical features and imaging findings. AJR Am J Roentgenol. 2008;191:423–431,

22. Vaglio A, Maritati F. Idiopathic Retroperitoneal Fibrosis. JASN. 2016;27 (7):1880-1889.

23. Marvisi C, Accorsi Buttini E, Vaglio A. Aortitis and periaortitis: The puzzling spectrum of inflammatory aortic diseases. Presse Med. 2020;49(1):104018. doi: 10.1016/j.lpm.2020.104018.

24. Nikiphorou E, Galloway J, Fragoulis GE. Overview of IgG4-related aortitis and periaortitis. A decade since their first description. Autoimmun Rev. 2020;19(12):102694. doi: 10.1016/j.autrev.2020.102694.

25. Palmisano A, Urban ML, Corradi D. Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis? Rheumatology (Oxford) 2015;54:2004-2009.

26. Kučera M. Lokalizované fibrotické procesy Referátový výběr z revmatologie. 1999;39(1):36-40.

27. Kučera M, Kratochvíl P. Lokalizované fibrotické procesy (onemocnění) léčebné možnosti Referátový výběr z revmatologie. 2000;40(4):273-277.

28. Martorana D, Marquez A, Carmona FD, et al. A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis. J Allergy Clin Immunol. Nov 2018;142(5):1662-1665.

29. Clevenger JA, Wang M, MacLennan GT, et al. Evidence for clonal fibroblast proliferation and autoimmune process in idiopathic retroperitoneal fibrosis. Hum Pathol. 2012;43:1875-1880.

30. Peisen F, Thaiss WM, Ekert K, et al. Retroperitoneal Fibrosis and its Differential Diagnoses: The Role of Radiological Imaging. Rofo. 2020;192(10):929-936.

31. Kawano M, Saeki T, Nakashima H. IgG4-related kidney disease and retroperitoneal fibrosis: An update. Mod Rheumatol. 2019;29(2):231-239.

32. Forestier A, Buob D, Mirault T, et al. No specific imaging pattern can help differentiate IgG4-related disease from idiopathic retroperitoneal fibrosis: 18 histologically proven cases. Clin Exp Rheumatol. 2018;36(3):371-375.

33. Rossi GM, Rocco R, Accorsi Buttini E, et al. Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. A. Intern Emerg Med. 2017;12:287-299.

34. Laco J, Podhola M, Kamarádová K, et al. Idiopathic vs. secondary retroperitoneal fibrosis: a clinicopathological study of 12 cases, with emphasis to possible relationship to IgG4-related disease. Virchows Archiv. 2013;463(5):721-730.

35. Hermanová M: Idiopatická retroperitoneální fibróza - editorial. Vnitřní lékařství. 2011;57(5):439-440.

36. Michaligová A, Plank L, Ježíková, A, et al. Ormondova choroba (idiopatická retroperitoneálna fibróza). Vnitřní lékařství. 2011;57(5):511-515.

37. Amis ES. Retroperitoneal fibrosis. AJR Am J Roengenol. 1991;157(2):321-329.

38. Sanders RC, Duffy T, Mcloughlin MG, Walsh PC. Sonography in the diagnosis of retroperitneal fibrosis. J Urol. 1977;118(6):944-946.

39. Vivas I, nicolas AI, Velazquez P, Elduayen B, fernandez-Villa T, Martinez-Cuesta A. Retroperitoneal fibrosis: typical and atypical manifestation. Br j Radiol 2000;73(866):214-222.

40. Van Bommel EF, Jansen I, Hendriksz TR, Aarnoudse AL. Idiopathic retroperitoneal fibrosis: prostective evaluation of incidence and clinicoradiologic presentationn. Medicine (Baltimore) 2009;88(4):193-201.

41. Caiafa RO, Vinuesa AS,Izquierdo RS, Brufau BP, Colella JRA, Molina CN. Retroperitoneal fibrosisi: role of imaging in Diagnosis and Follorw-up. RadioGraphics. 2013 33:2,535-552.

42. Miniberger M, Kašpar M, Drechslerová , et al. Ormondův syndrom (Syndrom retroperitoneální fibrózy). Diagnostické obtíže u necharakteristické formy onemocnění při vyšetření výpočetní tomografií. Česká radiologie. 1998;52(4):214-220.

43. Řehák Z, Němec P, Fabian , et al. Využití pozitronové emisní tomografie (18F-FDG PET) v diagnostice idiopatické retroperitoneální fibrózy – kazuistika Slovenská rádiológia. 2009;16(1):68- 73.

44. Roussel E, Callemeyn J, Van Moerkercke W. Standardized approach to idiopathic retroperitoneal fibrosis: a comprehensive review of the literature. Acta Clin Belg. 2020;75(4):239-244.

45. Wang K, Wang Z, Zeng Q, et al. Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis. PLoS One. 2021;16(2):e0245601. doi: 10.1371/ journal.pone.0245601.

46. Novák I, Morávek P, Baše J, et al. Dlouhodobé výsledky léčby nemocných s retroperitoneální fibrózou, Rozhledy v chirurgii. 1994;73(6):287-290.

47. Radoňák J, Vajo J, Toncr I, et al. Neobvyklá lokalizovaná forma retroperitoneálnej fibrózy. Rozhledy v chirurgii. 1999;78(8):378-380.

48. van Bommel EF, Siemes C, Hak LE, van der Veer SJ, Hendriksz TR. Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis.2007;49:615-625.

49. Mizushima I, Inoue D, Yamamoto M, et al. Clinical course after corticosteroid therapy in IgG4-related aortitis/periaortitis and periarteritis: a retrospective multicenter study. Arthritis Res Ther. 2014;16:R156. doi:10.1186/ar4671

50. Brandt AS, Kamper L, Kukuk S, et al. Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis. Urol Int. 2014;93:320-325.

51. van Bommel EF, Pelkmans LG, van Damme H, et al. Long-term safety and efficacy of a tamoxifen- based treatment strategy for idiopathic retroperitoneal fibrosis. Eur J InternMed. 2013;24:444-450.

52. Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomized controlled trial. Lancet. 2011;378:338-346.

53. Scavalli AS, Spadaro A, Riccieri V, et al. Long-term follow-up of low-dose methotrexate therapy in one case of idiopathic retroperitoneal fibrosis. Clin Rheumatol. 1995;14(4):481-484.

54. Alberici F, Palmisano A, Urban ML, et al. Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis. 2013;72:1584–1586.

55. Scavalli AS, Di Rocco G, Giannotti D, et al.Two-years follow-up of low-dose methotrexate and 6-methylprednisolone therapy in a patient with idiopathic retroperitoneal fibrosis. Eur Rev Med Pharmacol Sci. 2012;16(15):2171-4.

56. Binder M, Uhl M, Wiech T, et al. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis. 2012;71:311-312.

57. Kohler HP, Laeng RH, Egger C, et al.Systemische Fibrose (generalisierte Form des Morbus Ormond). Bericht über einen Fall, der mit Cyclophosphamid und Kortikosteroiden eine komplette Remission erlangte Schweiz Med Wochenschr.1995;125(44):2131-6.

58. Colomer Rubio E, Blanes Gallego A, et al. Mesenteric panniculitis with retroperitoneal involvement resolved after treatment with intravenous cyclophosphamide pulses. An Med Interna. 2003;20 (1):31-33.

59. Moroni G, Gallelli B, Banfi G, Sandri S, Messa P, Ponticelli C. Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and/or medical approaches. Nephrol. Dial. Transplant. 2006;21:2485– 90.

60. Průcha M, Kolombo I, Štádler P. Combination of steroids and azathioprine in the treatment of Ormond’s disease – a single centre retrospective analysis. PragueMed Rep. 2016;117:34–41. doi:10.14712/23362936.2016.3

61. Grotz W, von Zedtwitz I, Andre M, et al.Treatment of retroperitoneal fibrosis by mycophenolate mofetil and corticosteroids. Lancet. 1998;352(9135):1195.

62. Witschi M, Gugger M, Nicod LP. Treatment of mediastinal fibrosis with mycophenolate mofetil. Respiration. 2009;78(3):330-333.

63. Adler S, Lodermeyer S, Gaa J, et al.Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis. Rheumatology (Oxford). 2008;47(10):1535-1538.

64. Jois RN, Kerrigan N, Scott DG. Mycophenolate mofetil for maintenance of remission in idiopathic retroperitoneal fibrosis. Rheumatology (Oxford). 2007;46(4):717-718.

65. Khalil F, Mir MA, Venuto RC. Mycophenolate mofetil in the treatment of retroperitoneal fibrosis. Clin Rheumatol. 2008;27(5):679-681.

66. Scheel PJ Jr, Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med. 2011;154:31-36.

67. Scheel PJ Jr, Piccini J, Rahman MH, et al.Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis. J Urol. 2007;178(1):140-143.

68. Swartz RD, Lake AM, Roberts WW, et al. Idiopathic retroperitoneal fibrosis: a role for mycophenolate mofetil. Clin Nephrol. 2008;69(4):260-268.

69. Marzano A, Trapani A, Leone N, et al. Treatment of idiopathic retroperitoneal fibrosis using cyclosporin. Ann Rheum Dis. 2001;60(4):427-8.

70. Al-Harthy F, Esdaile J, Berean KW, et al. Multifocal idiopathic fibrosclerosis: treatment of 2 cases with cyclosporine. J Rheumatol. 2006;33(2):358-61. PMID: 16465670.

71. Marcolongo R, Tavolini IM, Laveder F, et al. Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med. 2004;116:194-197.

72. Maritati F, Corradi D, Versari A, et al. Rituximab therapy for chronic periaortitis. Ann Rheum Dis. 2012;71:1262-1264.

73. Almeqdadi M, Al-Dulaimi M, Perepletchikov A, et al.Rituximab for retroperitoneal fibrosis due to IgG4-related disease: A case report and literature review. Clin Nephrol Case Stud. 2018;6:4-10.

74. Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74:1171-1177.

75. Dedinská I, Svetlík D, Adamicova K, et al. Treatment of Ormond Disease and Idiopathic Membranous Glomerulonephritis by using Rituximab. Iran J Kidney Dis. 2016;10(5):332-335.

76. Hamdan A, Moeen Z, Tariq H, et al. An Interesting Case of Immunoglobulin G4-Related Retroperitoneal Fibrosis Treated With Rituximab. Cureus. 2021;13(9):e17940. doi:10.7759/cureus. 17940.

77. Wallwork R, Wallace Z, Perugino C, et al.Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Medicine (Baltimore). 2018;97(42):e12631. doi: 10.1097/MD.0000000000012631.

78. Boyeva V, Alabsi H, Seidman MA, et al. Use of rituximab in idiopathic; retroperitoneal fibrosis. BMC Rheumatol. 2020;4:40. doi: 10.1186/s41927-020-00140-9.

79. Urban ML, Maritati F, Palmisano A, et al. F. Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients. Ann Rheum Dis. 2020;79(3):433-434.

80. Fenaroli P, Maritati F, Vaglio A. Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis. Curr Rheumatol Rep. 2021;23(3):18.doi: 10.1007/s11926-020-00966-9.

81. Dattani R, Barwick TD, El Wardany G, et al. RaDaR Rare Disease Group (RDG). An international patient-centred study of retroperitoneal fibrosis. QJM. 2022;115(3):148-154. doi: 10.1093/ qjmed/hcaa327.

82. Hanazono A, Sanpei Y, Shimada H, et al. Remission of idiopathic retroperitoneal fibrosis by ofatumumab as a disease-modifying therapy for multiple sclerosis. eNeurologicalSci. 2022;29:100428. doi: 10.1016/j.ensci.2022.100428.

83. Benucci M, Damiani A, Li Gobbi F, et al. Jaccoud's arthropathy, an unusual manifestation of idiopathic retroperitoneal fibrosis: rapid improvement of symptoms after tocilizumab treatment. Reumatismo.2017;69(2):88-91.

84. Perrotta FM, Fici M, Guerra G, et al. Chronic periaortitis with retroperitoneal fibrosis successfully treated with first line tocilizumab monotherapy: a case report. Clin Exp Rheumatol. 2017;35 Suppl 103(1):226-227.

85. Vaglio A, Catanoso MG, Spaggiari L,et al.. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum. 2013;65(9):2469-75.

86. Loricera J, Blanco R, Castaeda S, et al. Tocilizumab in refractory aortitis: study on 16 patients and literature review. Clin Exp Rheumatol. 2014;32(3 Suppl 82):S79-89.

87. Catanoso MG, Spaggiari L, Magnani L, et al. Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol. 2012;30(5):776-8.

88. Gao H, Liu S, Mai Y, et al. Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis. Ann Rheum Dis. 2023:ard-2022-223736. doi:10.1136/ard- 2022-223736.

89. Hirose M, Ishimaru Y, Sakata S, et al. Rapid Shrinkage of Retroperitoneal Lymphangioleiomyoma after Sirolimus Initiation. Intern Med. 2022;61(13):2081-2082. doi: 10.2169/internalmedicine. 8685-21.

90. Yao W, Li K, Wang Z, et al. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus. Pediatr Dermatol. 2020;37(4):677-680. doi: 10.1111/pde.14157.

91. Lecuelle D, Basille D, Renard C, et al. Highly effective sirolimus therapy for abdominal lymphangioleiomyoma. Respir Med Res. 2019;75:32-34. doi: 10.1016/j.resmer.2019.02.002.

92. Campochiaro C, Della-Torre E, Lanzillotta M, et al. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. Eur J Intern Med. 2020;74:92-98. doi: 10.1016/j.ejim.2019.12.029.

93. Ščudla V, Horák P. Diferenciální diagnostika urychlení sedimentace erytrocytů. Vnitřní Lék. 2023; 69 (1): 48-56.

94. Mayer J, Pospíšil Z. Mechanismus sedimentace erytrocytů – víme dnes více než Robin Fahraeus? Vnitřní lékí. 1993;39(6):604-612.

95. Ščudla V, Horák P, Karásek D, et al. Základy diferenciální diagnostiky ve vnitřním lékařství. Nakladatelství Palackého univerzity 2021, 696 s.

96. Pelkmans LG, Aarnoudse AJ, Hendriksz TR, et al. Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant. 2012; 27: 2819-2825.

97. Vaglio A, Versari A, Fraternali A, et al. (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis. Arthritis Rheum. 2005;53:122-125.

98. Jansen I, Hendriksz TR, Han SH, et al. (18)F-fluorodeoxyglucose position emission tomography (FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Eur J Intern Med. 2010; 21:216-221.

99. Němec P, Řehák Z, Fabián P. Využití pozitronové emisní tomografie (18F- FDG PET) v diagnostice chronických periaortitid. Vnitř.Lék. 2008;54(11):1093-1099.

100. Tatoglu MT, Uslu H, Ibisoglu E. The value of (18)F-FDG PET/CT in Diagnosis and Evaluation of Response to Treatment in Retroperitoneal Fibrosis. Nuklearmedizin. 2021;60(5):381- 382. doi: 10.1055/a-1429-2237.

101. Crane A, Eltemamy M, Shoskes D. Transplant immunosuppressive drugs in urology. Transl Androl Urol. 2019;8(2):109-117. doi:10.21037/tau.2018.07.12.

Labels

Diabetology Endocrinology Internal medicine

Barakat syndrome

Finerenone

Whats new in ESC Guidelines for the management of valvular heart disease?

Komentář k článku „Jak přesvědčit pacienta odmítajícího kolonoskopické vyšetření – kvalitativní studie“ z psychologického hlediska

Article was published in

Internal Medicine

2023 Issue E-3